Law360 (June 15, 2020, 3:52 PM EDT) — The U.S. Supreme Court on Monday declined a request from generic drugmakers to review a discovery dispute between them and states attorneys general and drug buyers suing over an alleged industry-wide conspiracy to fix generic drug prices.

The justices denied a petition for review from generic heavyweights — including Actavis, Amneal, Impax, Sandoz and Teva — that were looking to fix what they called an “inverted discovery procedure” in the wide-ranging multidistrict litigation over generic drug prices.

In a statement Monday, Connecticut Attorney General William Tong, who is helping lead the coalition of state enforcers, said the companies had sought review…